Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.
Bottom Line: Plasma levels of interleukin (IL)-17, IL-22, IL-23, IL-1β, IL-6, and transforming growth factor (TGF)-β1 were significantly increased in blood and bone marrow in AML patients compared with healthy donors.Patients with high Th17 cell frequency had poor prognosis, whereas patients with high Th1 cell frequency had prolonged survival.Combined analysis of Th1 and Th17 cell frequencies improved the ability to predict patient outcomes.
Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.Show MeSH
Related in: MedlinePlus
Mentions: We evaluated the levels of Th17-producing cytokines to further confirm increased existence of Th17 cells in AML patients. Significant elevation of IL-17A, IL-22, and IL-23, three cytokines secreted by Th17 cells, were observed in both PB and BM from untreated AML patients compared with those from healthy donors as measured by ELISA (Fig. 3a). We next evaluated other cytokines that had been reported to associate with the generation and differentiation of human Th17 cells. As shown in Figure 3(b), higher levels of IL-1β, IL-6, and TGF-β1 were observed in PB and BM from AML patients compared with those from healthy donors. These results suggested that these proinflammatory cytokines present in AML BM microenvironment might modulate the generation and differentiation of Th17 cells.
Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.